___

• 1. Shende, P., Basarkar, V. (2019). Recent trends and advances in microbe-based drug delivery systems. [CrossRef]
• 2. Fu, G.-F., Li, X., Hou, Y.-Y., Fan, Y.-R., Liu, W.-H., Xu, G.-X. (2005). Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Therapy, 12, 133–140. [CrossRef]
• 3. Aminu, N., Bello, I., Umar, N. M., Tanko, N., Aminu, A., Audu, M. M. (2020). The influence of nanoparticulate drug delivery systems in drug therapy. In Journal of Drug Delivery Science and Technology (Vol. 60). [CrossRef]
• 4. C. Tuba; Hascicek, S.T. (2009). Polimerik nanopartikuler ilaç taşıyıcı sistemlerde yüzey modifikasyonu. Ankara Universitesi Eczacilik Fakultesi Dergisi, 38(2), 137–154. [CrossRef]
• 5. Erel-Akbaba, G.,Akbaba, H. (2021). Investigation of the potential therapeutic effect of cationic lipoplex mediated fibroblast growth factor-2 encoding plasmid DNA delivery on wound healing. DARU Journal of Pharmaceutical Sciences. [CrossRef]
• 6. Torchilin, V. P. (2014). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature Reviews Drug Discovery, 13(11), 813–827. [CrossRef]
• 7. Zhang, H., Liu, J., Chen, Q., Mi, P. (2020). Ligand-installed anti-VEGF genomic nanocarriers for effective gene therapy of primary and metastatic tumors. Journal of Controlled Release, 320, 314–327. [CrossRef]
• 8. Erel-Akbaba, G., Carvalho, L. A., Tian, T., Zinter, M., Akbaba, H., Obeid, P. J., Chiocca, E. A., Weissleder, R., Kantarci, A. G., & Tannous, B. A. (2019). Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy. ACS Nano, 13(4), 4028–4040. [CrossRef]
• 9. Maslanka Figueroa, S., Fleischmann, D., Goepferich, A. (2021). Biomedical nanoparticle design: What we can learn from viruses. In Journal of Controlled Release (Vol. 329, pp. 552–569). [CrossRef]
• 10. Parodi, A., Molinaro, R., Sushnitha, M., Evangelopoulos, M., Martinez, J. O., Arrighetti, N., Corbo, C., Tasciotti, E. (2017). Bio-inspired engineering of cell- and virus-like nanoparticles for drug delivery. Biomaterials, 147, 155–168. [CrossRef]
• 11. Unzueta, U., Céspedes, M. V., Vázquez, E., Ferrer-Miralles, N., Mangues, R., Villaverde, A. (2015). Towards protein-based viral mimetics for cancer therapies. In Trends in Biotechnology (Vol. 33, Issue 5, pp. 253–258). [CrossRef]
• 12. Franco, O. L., Qian, Y., Chen, S., Zhang, J., Yang, G. (2019). Bioinspired and Biomimetic Nanotherapies for the Treatment of Infectious Diseases. [CrossRef]
• 13. Schwarz, B., Uchida, M., Douglas, T. (2017). Biomedical and Catalytic Opportunities of Virus-Like Particles in Nanotechnology. In Advances in Virus Research (Vol. 97, pp. 1–60). [CrossRef]
• 14. Kanekiyo, M., Buck, C. B. (2017). Virus-Like Particle and Nanoparticle Vaccines. In Human Vaccines: Emerging Technologies in Design and Development (pp. 87–98). [CrossRef]
• 15. Kushnir, N., Streatfield, S. J., Yusibov, V. (2012). Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development. In Vaccine (Vol. 31, Issue 1, pp. 58–83). [CrossRef]
• 16. Gadekar, V., Borade, Y., Kannaujia, S., Rajpoot, K., Anup, N., Tambe, V., Kalia, K., Tekade, R. K. (2021). Nanomedicines accessible in the market for clinical interventions. In Journal of Controlled Release (Vol. 330, pp. 372–397). [CrossRef]
• 17. Yilmaz, I. C., Ipekoglu, E. M., Bulbul, A., Turay, N., Yildirim, M., Evcili, I., Yilmaz, N. S., Guvencli, N., Aydin, Y., Gungor, B., Saraydar, B., Bartan, A. G., Ibibik, B., Bildik, T., Baydemir, İ., Sanli, H. A., Kayaoglu, B., Ceylan, Y., Yildirim, T., Gursel, M. (2021). Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection. Allergy: European Journal of Allergy and Clinical Immunology. [CrossRef]
• 18. Mbah, C. C., Attama, A. A. (2018). Vesicular carriers as innovative nanodrug delivery formulations. In Organic Materials as Smart Nanocarriers for Drug Delivery (pp. 519–559). [CrossRef]
• 19. Loo, Y. S., Bose, R. J., McCarthy, J. R., Mat Azmi, I. D., Madheswaran, T. (2021). Biomimetic bacterial and viral-based nanovesicles for drug delivery, theranostics, and vaccine applications. In Drug Discovery Today (Vol. 26, Issue 4, pp. 902–915). [CrossRef]
• 20. Sabu, C., Rejo, C., Kotta, S., Pramod, K. (2018). Bioinspired and biomimetic systems for advanced drug and gene delivery. In Journal of Controlled Release (Vol. 287, pp. 142–155). [CrossRef]
• 21. Almeida, J. D., Edwards, D. C., Brand, C. M., Heath, T. D. (1975). FORMATION OF VIROSOMES FROM INFLUENZA SUBUNITS AND LIPOSOMES. The Lancet, 306(7941), 899–901. [CrossRef]
• 22. Daemen, T., De Mare, A., Bungener, L., De Jonge, J., Huckriede, A., Wilschut, J. (2005). Virosomes for antigen and DNA delivery. In Advanced Drug Delivery Reviews (Vol. 57, Issue 3 SPEC. ISS., pp. 451–463). [CrossRef]
• 23. Felnerova, D., Viret, J. F., Glück, R., Moser, C. (2004). Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. In Current Opinion in Biotechnology (Vol. 15, Issue 6, pp. 518–529). Elsevier Current Trends. [CrossRef]
• 24. Zheng, B., Peng, W., Guo, M., Huang, M., Gu, Y., Wang, T., Ni, G., Ming, D. (2021). Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19. Chemical Engineering Journal, 418, 129392. [CrossRef]
• 25. Huda, S., Alam, M. A., Sharma, P. K. (2020). Smart nanocarriers-based drug delivery for cancer therapy: An innovative and developing strategy. In Journal of Drug Delivery Science and Technology (Vol. 60, p. 102018). [CrossRef]
• 26. Correia-Pinto, J. F., Csaba, N., Alonso, M. J. (2013). Vaccine delivery carriers: Insights and future perspectives. International Journal of Pharmaceutics, 440(1), 27–38. [CrossRef]
• 27. Whitesides, G. M., Grzybowski, B. (2002). Self-assembly at all scales. In Science (Vol. 295, Issue 5564, pp. 2418–2421). [CrossRef]
• 28. Delfi, M., Sartorius, R., Ashrafizadeh, M., Sharifi, E., Zhang, Y., De Berardinis, P., Zarrabi, A., Varma, R. S., Tay, F. R., Smith, B. R., Makvandi, P. (2021). Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy. In Nano Today (Vol. 38, p. 101119). [CrossRef]
• 29. Khyatti, M., Patel, P. C., Stefanescu, I., Menezes, J. (1991). Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity. Journal of Virology, 65(2), 996–1001. [CrossRef]
• 30. Kanekiyo, M., Bu, W., Joyce, M. G., Meng, G., Whittle, J. R. R., Baxa, U., Yamamoto, T., Narpala, S., Todd, J. P., Rao, S. S., McDermott, A. B., Koup, R. A., Rossmann, M. G., Mascola, J. R., Graham, B. S., Cohen, J. I., Nabel, G. J. (2015). Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell, 162(5), 1090–1100. [CrossRef]
• 31. Xu, C. H., Ye, P. J., Zhou, Y. C., He, D. X., Wei, H., Yu, C. Y. (2020). Cell membrane-camouflaged nanoparticles as drug carriers for cancer therapy. Acta Biomaterialia, 105, 1–14. [CrossRef]
• 32. Choi, B., Park, W., Park, S. Bin, Rhim, W. K., Han, D. K. (2020). Recent trends in cell membrane-cloaked nanoparticles for therapeutic applications. Methods, 177(October 2019), 2–14. [CrossRef]
• 33. Li, R., He, Y., Zhang, S., Qin, J., Wang, J. (2018). Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment. Acta Pharmaceutica Sinica B, 8(1), 14–22. [CrossRef]
• 34. Zhai, Y., Su, J., Ran, W., Zhang, P., Yin, Q., Zhang, Z., Yu, H., Li, Y. (2017). Preparation and Application of Cell Membrane-Camouflaged Nanoparticles for Cancer Therapy. Theranostics, 7(10), 2575–2592. [CrossRef]
• 35. Dash, P., Piras, A. M., Dash, M. (2020). Cell membrane coated nanocarriers - an efficient biomimetic platform for targeted therapy. Journal of Controlled Release, 327, 546–570. [CrossRef]
• 36. Yoo, J. W., Irvine, D. J., Discher, D. E., Mitragotri, S. (2011). Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nature Reviews Drug Discovery, 10(7), 521–535. [CrossRef]
• 37. Föller, M., Huber, S. M., Lang, F. (2008). Erythrocyte programmed cell death. IUBMB Life, 60(10), 661–668. [CrossRef]
• 38. Pierige, F., Serafini, S., Rossi, L., Magnani, M. (2008). Cell-based drug delivery. Advanced Drug Delivery Reviews, 60(2), 286–295. [CrossRef]
• 39. Jia, Y., Duan, L., Li, J. (2016). Hemoglobin-Based Nanoarchitectonic Assemblies as Oxygen Carriers. Advanced Materials, 28(6), 1312–1318. [CrossRef]
• 40. Hu, C.-M. J., Fang, R. H., Zhang, L. (2012). Erythrocyte-Inspired Delivery Systems. Advanced Healthcare Materials, 1(5), 537–547. [CrossRef]
• 41. Legrand, N., Huntington, N. D., Nagasawa, M., Bakker, A. Q., Schotte, R., Strick-Marchand, H., Geus, S. J. de, Pouw, S. M., Böhne, M., Voordouw, A., Weijer, K., Santo, J. P. Di, Spits, H. (2011). Functional CD47/signal regulatory protein alpha (SIRPα) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo. Proceedings of the National Academy of Sciences, 108(32), 13224–13229. [CrossRef]
• 42. Xia, Q., Zhang, Y., Li, Z., Hou, X., Feng, N. (2019). Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharmaceutica Sinica B, 9(4), 675–689. [CrossRef]
• 43. Hamidi, M., Tajerzadeh, H. (2003). Carrier erythrocytes: An overview. Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents, 10(1), 9–20. [CrossRef]
• 44. Fang, R. H., Hu, C. M. J., Chen, K. N. H., Luk, B. T., Carpenter, C. W., Gao, W., Li, S., Zhang, D. E., Lu, W., Zhang, L. (2013). Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale, 5(19), 8884–8888. [CrossRef]
• 45. Kroll, A.V., Frang, R.H., Zhang, L. (2017). Biointerfacing and Applications of Cell Membrane-Coated Nanoparticles. Bioconjugate Chemistry, 28(1), 23–32. [CrossRef]
• 46. Fang, J., Nakamura, H., Maeda, H. (2011). The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced Drug Delivery Reviews, 63(3), 136–151. [CrossRef]
• 47. Chai, Z., Hu, X., Wei, X., Zhan, C., Lu, L., Jiang, K., Su, B., Ruan, H., Ran, D., Fang, R. H., Zhang, L., Lu, W. (2017). A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery. Journal of Controlled Release, 264, 102–111. [CrossRef]
• 48. Li, A., Zhao, J., Fu, J., Cai, J., Zhang, P. (2021). Recent advances of biomimetic nano-systems in the diagnosis and treatment of tumor. Asian Journal of Pharmaceutical Sciences, 16(2), 161–174. [CrossRef]
• 49. Gao, C., Wu, Z., Lin, Z., Lin, X., He, Q. (2016). Polymeric capsule-cushioned leukocyte cell membrane vesicles as a biomimetic delivery platform. Nanoscale, 8(6), 3548–3554. [CrossRef]
• 50. Corbo, C., Parodi A., Evangelopoulos M., Engler R.K., Matsunami, Engler A.C, Tasciotti E. (2015). Proteomic Profiling of a Biomimetic Drug Delivery Platform. Current Drug Targets, 16(13), 1540–1547. [CrossRef]
• 51. Huang, Y., Gao, X., Chen, J. (2018). Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy. Acta Pharmaceutica Sinica B, 8(1), 4–13. [CrossRef]
• 52. JA, B. (2005). Regulatory T-cell therapy: is it ready for the clinic? Nature Reviews. Immunology, 5(4), 343–349. [CrossRef]
• 53. Wang, Q., Cheng, H., Peng, H., Zhou, H., Li, P. Y., Langer, R. (2015). Non-genetic engineering of cells for drug delivery and cell-based therapy. Advanced Drug Delivery Reviews, 91, 125–140. [CrossRef]
• 54. Patel, S. R., Hartwig, J. H., Italiano, J. E. (2005). The biogenesis of platelets from megakaryocyte proplatelets. The Journal of Clinical Investigation, 115(12), 3348–3354. [CrossRef]
• 55. Harker, L. A., Roskos, L. K., Marzec, U. M., Carter, R. A., Cherry, J. K., Sundell, B., Cheung, E. N., Terry, D., Sheridan, W. (2000). Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood, 95(8), 2514–2522. [CrossRef]
• 56. Chen, Y., Zhao, G., Wang, S., He, Y., Han, S., Du, C., Li, S., Fan, Z., Wang, C., Wang, J. (2019). Platelet-membrane-camouflaged bismuth sulfide nanorods for synergistic radio-photothermal therapy against cancer. Biomaterials Science, 7(8), 3450–3459. [CrossRef] 57. Li, Z., Hu, S., Cheng, K. (2018). Platelets and their biomimetics for regenerative medicine and cancer therapies. Journal of Materials Chemistry. B, 6(45), 7354–7365. [CrossRef]
• 58. Wu, M., Le, W., Mei, T., Wang, Y., Chen, B., Liu, Z., Xue, C. (2019). Cell membrane camouflaged nanoparticles: a new biomimetic platform for cancer photothermal therapy. International Journal of Nanomedicine, Volume 14, 4431–4448. [CrossRef]
• 59. Liu, Y., Luo, J., Chen, X., Liu, W., Chen, T. (2019). Cell Membrane Coating Technology: A Promising Strategy for Biomedical Applications. Nano-Micro Letters, 11(1). [CrossRef]
• 60. Quesada, M. P., García-Bernal, D., Pastor, D., Estirado, A., Blanquer, M., García-Hernández, A. M., Moraleda, J. M., Martínez, S. (2019). Safety and Biodistribution of Human Bone Marrow-Derived Mesenchymal Stromal Cells Injected Intrathecally in Non-Obese Diabetic Severe Combined Immunodeficiency Mice: Preclinical Study. Tissue Engineering and Regenerative Medicine, 16(5), 525–538. [CrossRef]
• 61. Sherr, C. J. (1996). Cancer cell cycles. Science, 274(5293), 1672–1674. [CrossRef]
• 62. Yang, R., Xu, J., Xu, L., Sun, X., Chen, Q., Zhao, Y, Liu, Z. (2018). Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination. ACS Nano, 12(6), 5121–5129. [CrossRef]
• 63. Stremersch, S., De Smedt, S. C., & Raemdonck, K. (2016). Therapeutic and diagnostic applications of extracellular vesicles. Journal of Controlled Release, 244, 167–183. [CrossRef]
• 64. Tian, T., Zhang, H. X., He, C. P., Fan, S., Zhu, Y. L., Qi, C., Huang, N. P., Xiao, Z. D., Lu, Z. H., Tannous, B. A., & Gao, J. (2018). Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials, 150, 137–149. [CrossRef]
• 65. Conde-Vancells, J., Rodriguez-Suarez, E., Embade, N., Gil, D., Matthiesen, R., Valle, M., Falcon-Perez, J.M.,. (2008). Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. Journal of Proteome Research, 7(12), 5157–5166.
• 66. Camussi, G., Deregibus, M.C., Bruno, S., Cantaluppi V., Biancone L. (2010). Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney International, 78(9), 838–848. [CrossRef]
• 67. Kotmakcı, M., & Erel-Akbaba, G. (2017). Exosome isolation: is there an optimal method with regard to diagnosis or treatment?, Novel Implications of Exosomes in Diagnosis and Treatment of Cancer and Infectious Diseases. Intech Open, 163. [CrossRef]
• 68. Sun, D., Zhuang, X., Xiang, X., Liu, Y., Zhang, S., Liu, C, Zhang, H.G., (2010). A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Molecular Therapy : The Journal of the American Society of Gene Therapy, 18(9), 1606–1614. [CrossRef]
• 69. Jo, W., Jeong, D., Kim, J., Cho, S., Jang, S., Han, C., Kang, J. Y., Gho Y. S., Park, J. (2014). Microfluidic fabrication of cell-derived nanovesicles as endogenous RNA carriers. Lab on a Chip, 14(7), 1261–1269. [CrossRef]
• 70. Jang, S.C., Kim, O.Y., Yoon, C.M., Choi, D.S., Roh, T.Y., Park, J. … Gho, Y.S. (2013). Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano, 7(9), 7698–7710. [CrossRef]
• 71. Hosseinidoust, Z., Mostaghaci, B., Yasa, O., Park, B. W., Singh, A. V., & Sitti, M. (2016). Bioengineered and biohybrid bacteria-based systems for drug delivery. In Advanced Drug Delivery Reviews (Vol. 106, pp. 27–44). [CrossRef]
• 72. Poo, H., Pyo, H. M., Lee, T. Y., Yoon, S. W., Lee, J. S., Kim, C. J., Sung, M. H., & Lee, S. H. (2006). Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice. International Journal of Cancer, 119(7), 1702–1709. [CrossRef]
• 73. Harisa, G. I., Sherif, A. Y., Youssof, A. M. E., Alanazi, F. K., & Salem-Bekhit, M. M. (2020). Bacteriosomes as a Promising Tool in Biomedical Applications: Immunotherapy and Drug Delivery. AAPS PharmSciTech, 21(5), 1–13. [CrossRef]
• 74. Claesen, J., & Fischbach, M. A. (2015). Synthetic microbes as drug delivery systems. ACS Synthetic Biology, 4(4), 358-364. [CrossRef]
• 75. Rabanel, J. M., Hildgen, P., & Banquy, X. (2014). Assessment of PEG on polymeric particles surface, a key step in drug carrier translation. In Journal of Controlled Release (Vol. 185, Issue 1, pp. 71–87). [CrossRef]
• 76. Wang, R., Yan, H., Yu, A., Ye, L., & Zhai, G. (2021). Cancer targeted biomimetic drug delivery system. Journal of Drug Delivery Science and Technology, 63(January), 102530. [CrossRef]
• 77. Chen, W., Wang, Y., Qin, M., Zhang, X., Zhang, Z., Sun, X., & Gu, Z. (2018). Bacteria-Driven Hypoxia Targeting for Combined Biotherapy and Photothermal Therapy. ACS Nano, 12(6), 5995–6005. [CrossRef]
• 78. Zhang, M., Li, M., Du, L., Zeng, J., Yao, T., & Jin, Y. (2020). Paclitaxel-in-liposome-in-bacteria for inhalation treatment of primary lung cancer. International Journal of Pharmaceutics, 578, 119177. [CrossRef]
• 79. Langemann, T., Koller, V. J., Muhammad, A., Kudela, P., Mayr, U. B., & Lubitz, W. (2010). The b1. Hosseinidoust Z, Mostaghaci B, Yasa O, Park BW, Singh AV, Sitti M. Bioengineered and biohybrid bacteria-based systems for drug delivery. Vol. 106, Advanced Drug Delivery Reviews. [CrossRef]
• 80. Youssof, A. M. E., Alanazi, F. K., Salem-Bekhit, M. M., Shakeel, F., & Haq, N. (2019). Bacterial Ghosts Carrying 5-Fluorouracil: A Novel Biological Carrier for Targeting Colorectal Cancer. AAPS PharmSciTech, 20(2), 1–12. [CrossRef]
• 81. Kudela, P., Koller, V. J., & Lubitz, W. (2010). Bacterial ghosts (BGs)-Advanced antigen and drug delivery system. Vaccine, 28(36), 5760–5767. [CrossRef]
• 82. Moghaddam, A. B., Namvar, F., Moniri, M., Tahir, P. M., Azizi, S., & Mohamad, R. (2015). molecules Nanoparticles Biosynthesized by Fungi and Yeast: A Review of Their Preparation, Properties, and Medical Applications. Molecules, 20, 16540–16565. [CrossRef]
• 83. Hu, X., & Zhang, J. (2017). Yeast capsules for targeted delivery: the future of nanotherapy? Nanomedicine, 12(9), 955–957. [CrossRef]
• 84. Hu, X., Yang, G., Chen, S., Luo, S., & Zhang, J. (2020). Biomimetic and bioinspired strategies for oral drug delivery. Biomaterials Science, 8(4), 1020–1044. [CrossRef]